Businesses, not tickers
We buy companies the way owners do — understanding the model, the unit economics, and the competitive structure before we measure the price.
JBP Capital is a private long-term investment fund. We buy companies as owners, with multi-year horizons, and publish open research on every business we analyze and every position we hold.
Every position has to pass a written research piece anyone can read: the thesis, the numbers, the risks. If we can't defend it on a single page, we can't defend it with capital either.
Three ideas, each simple on its own — deeply useful when stitched together into a disciplined process.
We buy companies the way owners do — understanding the model, the unit economics, and the competitive structure before we measure the price.
We pay less than what a business is worth. The patience to wait for fair prices is the only sustainable edge we know of.
We think in 5–10 year blocks, not in quarters. Volatility is the toll we pay for compounding returns.
Thesis first, numbers second, context always. Our research isn't decoration — it's the foundation we use to decide when to buy and when to keep watching.
Why we believe today's price discounts only the auto business — and prices the FSD optionality at essentially zero.
RSI 87. Price 0.06% from the 52-week high. 1-month ETF flows just turned negative for the first time in months. And 33.7% of the index sits in seven stocks whose Q1 reports are the next two weeks. The cleanest 'be careful here' setup we've seen in the file in months.
Forward P/E of 150x. FCF of $5B against $25B of guided capex. Inventory growing by 50K units in one quarter. And still — Cybercab production starting, robotaxi paid miles doubling, and Optimus moving to manufacturing. How we think about that contradiction.
March printed the largest Western gold-ETF outflow on record. Q1 saw the largest Asian inflow on record. Total holdings hit a fresh all-time high. Sell-side targets stayed bullish. Why the consolidation looks more like a handoff than a top.
Leads capital allocation and macro research. Background in product and technology; brought that systemic discipline to the portfolio.
Leads bottom-up analysis: DCF models, filings, thesis tracking. Believes good research is 80% patient reading.
One email every time we publish a new thesis. No spam, no webinar invites — just the research, direct.